Growth still comes with a control problem
- Product revenue grew 14.8% in Q1 2026, slower than 16.4% for full-year 2025.
- Filtration is still the largest franchise, but it grew only 4.1% in Q1 2026.
- Process Analytics grew 52.0%, helped by $2.4 million from the 908 Devices PAT portfolio.
- Gross margin improved to 55.7% from 54.0%, so the margin story is not broken.
- The two remaining internal control weaknesses were still not fixed as of March 31, 2026.
Good tools, weak controls
Repligen still has a real business. Its products help drugmakers and contract manufacturers make biologic drugs, which are complex medicines made from living cells. Product revenue grew 14.8% in Q1 2026, and gross margin improved to 55.7%. That keeps the bull case alive.
The problem is that growth is slowing. Full-year 2025 product revenue grew 16.4%, so Q1 2026 was another step down. Filtration, the largest franchise, grew only 4.1%. Process Analytics was the bright spot at 52.0% growth, but $2.4 million came from the acquired 908 Devices PAT portfolio, so the organic growth rate is still an open question.
The bigger worry is trust. Repligen still had two serious internal control weaknesses as of March 31, 2026. These are gaps in the systems and checks used to make sure the books are right. One is tied to IT access and change controls. The other is tied to inventory valuation and the financial close process.
The stock needs proof, not promises. If management fixes one or both weaknesses in 2026 and revenue growth settles in the mid-teens, the story could improve. If growth keeps sliding while the control issues stay open, investors may keep applying a discount.
Selling picks for biologic factories
Repligen makes money by selling tools and systems used inside biologic drug factories. Its customers include large biopharma companies and CDMOs, which are outside manufacturers hired to develop or make drugs.
The company reports one bioprocessing business. Inside that business, the main product franchises are Filtration, Chromatography, Process Analytics, Proteins and Other. These products touch both upstream steps, where cells are grown, and downstream steps, where the drug is purified and prepared.
Growth comes from three places: customers building or improving biologic manufacturing lines, Repligen launching better tools, and acquisitions that add new products. Recent deals include FlexBiosys, Metenova, Tantti Laboratory and the 908 Devices PAT portfolio.
The model breaks if biotech funding slows, drugmakers delay factory spending, or customers use up inventory instead of ordering new parts. It also breaks if acquisitions add revenue but make the control environment harder to manage. That last risk matters now because the company is still fixing basic financial controls.
Where the products fit
Filtration
Filtration helps separate, concentrate and process biologic materials. It was the largest Q1 2026 franchise at $95.8 million of product revenue, but growth was only 4.1%.
Chromatography
Chromatography products help purify biologic drugs by separating wanted molecules from unwanted ones. This franchise grew 26.9% in Q1 2026.
Process Analytics
Process Analytics tools help customers see what is happening during drug development and manufacturing. It grew 52.0% in Q1 2026, with help from the 908 Devices PAT portfolio.
Proteins
Proteins products support biologic drug manufacturing workflows. This franchise recovered from earlier customer-specific pressure and reached $32.8 million of Q1 2026 product revenue.
Single-use and mixing products
FlexBiosys added single-use bioprocessing products, and Metenova added magnetic mixing technologies. These deals broaden the platform but also add integration work.
Tantti chromatography beads
Tantti added macroporous chromatography beads aimed at newer drug types such as viral vectors and other large molecules. It gives Repligen another way to serve cell and gene therapy customers.
One segment, several franchises
Repligen reports one bioprocessing business segment. The mix below uses Q1 2026 product revenue by franchise, so it is a product mix, not a separate legal segment view.
What could go wrong
Control fixes take too long
High impact · High oddsRepligen still had two material weaknesses as of March 31, 2026. These are serious gaps in internal control over financial reporting. If they stay open, investors may question the quality of reported numbers even if sales grow.
Growth resets lower
High impact · Medium oddsProduct revenue growth slowed to 14.8% in Q1 2026 from 16.4% for full-year 2025. That is still growth, but the direction matters because the stock needs a strong growth profile to support its price. A move below mid-teens growth would make the control risk harder to accept.
Filtration stays weak
Medium impact · Medium oddsFiltration is the biggest franchise, with $95.8 million of Q1 2026 product revenue. It grew only 4.1% in the quarter. If the largest line stays slow, faster growth in smaller lines may not be enough to lift the whole company.
Analytics growth is acquisition-heavy
Medium impact · Medium oddsProcess Analytics grew 52.0% in Q1 2026, but the acquired 908 Devices PAT portfolio added $2.4 million of revenue. The open question is how much of the growth came from existing products. If most growth is bought, investors may value it less highly.
Inventory and close process errors
High impact · Medium oddsOne remaining control weakness relates to inventory valuation and the financial statement close process. That matters because Repligen recorded $36.0 million in inventory adjustments in 2024. More inventory surprises would hurt confidence in margins and reported earnings.
In one breath
What does Repligen actually do?
Repligen sells tools used to make biologic drugs. These tools help drugmakers filter, purify, mix and monitor materials during manufacturing.
Why are investors worried about RGEN?
The company is still growing, but growth slowed in Q1 2026. Repligen also has two unresolved internal control weaknesses, which means its financial reporting checks are not yet strong enough.
What is the main bull case for Repligen?
The bull case is that biologic drug manufacturing keeps expanding and Repligen remains a key supplier. If growth stabilizes and the company fixes its controls, investor trust could improve.
What should I watch next?
Watch for remediation of the two remaining control weaknesses. Also watch product revenue growth, Filtration growth and whether Process Analytics growth is mostly organic or deal-driven.